Sparrow Pharmaceuticals presented new data at the European Congress of Endocrinology 2021 on 22-26 May 2021 as a poster presentation, “SPI-62: An investigational HSD-1 inhibitor for the treatment of Cushing syndrome”.

Sparrow Pharmaceuticals announced the closing of a $50 million Series A financing. OrbiMed led the investment round with participation by RiverVest Venture Partners and U.S. Venture Partners (USVP).